Additionally, patients who developed dermatitis showed decreased levels of plasma CX3CL1, vascular endothelial growth factor-alpha (VEGF-α), and MHCI-related peptides 1–3 months after ICI treatment (Tyan et al., 2021). The gene discussed is CX3CL1; the disease is dermatitis.